French pharma major Sanofi (Euronext: SAN) has added to Mylan’s (Nasdaq: MYL) woes over the Netherlands-incorporated drugmaker’s EpiPen (epinephrine) Auto-Injector device.
Already the subject of litigation over Mylan’s policy of persistently raising the price of the allergy treatment in the USA, now the EpiPen is at the center of a new lawsuit filed by Sanofi on the Monday.
The antitrust litigation, lodged in the US federal court in New Jersey, accuses Mylan of anticompetitive conduct after Sanofi launched a competing device in the USA with a product known as Auvi-Q.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze